Share This Author
NAFLD: a multisystem disease.
Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
Further research is needed in NAFLD to establish the dose of long-chain omega-3 fatty acids as a treatment, determine the duration of therapy, and test whether there is benefit on the different component features ofNAFLD (hepatic fat, inflammation, and fibrosis).
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
The evidence to date linking NAFLD with cardiovascular disease is discussed, the likely mechanisms underlying this association are reviewed, as well as, from a cardiologist's perspective, current and potential future treatment options for this increasingly prevalent disease are summarized.
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
NAFLD is significantly associated with a twofold increased risk of incident diabetes, however, the observational design of the eligible studies does not allow for proving causality.
Maternal high‐fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression
Maternal fat intake contributes toward the NAFLD progression in adult offspring, which is mediated through impaired hepatic mitochondrial metabolism and up‐regulated hepatic lipogenesis.
Depot-related gene expression in human subcutaneous and omental adipocytes.
Of the mRNAs examined to date, only leptin and cIAP2 show consistent site-related expression, suggesting that these molecules may have important roles in determining functional properties particular to individual adipose depots.
NAFLD as a driver of chronic kidney disease.
CKD and nonalcoholic fatty liver disease.
The clinical implication for these findings is that patients with nonalcoholic fatty liver disease may benefit from more intensive surveillance or early treatment interventions to decrease the risk of CKD.
Obesity Is a Risk Factor for Greater COVID-19 Severity
The association between obesity and COVID-19 severity of illness among patients with laboratory-confirmed SARS-CoV-2 infection is investigated and obesity was defined as BMI ≥25 kg/m2 in this Asian population.